title: Requirement of MEF2D in the induced differentiation of HL60 promyeloid cells.
abstract: The regulatory role of MEF2 (myocyte enhancer binding factor 2) proteins in nonmuscle tissues has not been well characterized. We examined the expression of MEF2 family members, namely, MEF2A, -B, -C, and -D, in the differentiation of HL60 promyeloid cells and observed the remarkable increase in the expressions of MEF2A and MEF2D proteins during the differentiation process into monocytes. To examine the role of MEF2, we expressed a dominant-negative form of MEF2D, without its transactivation domain, in HL60 cells. When the HL60 cell line expressing the mutant MEF2D was induced to differentiate by VitD(3) treatment, cell surface expression of CD14 and the ability to reduce NBT, which are important characteristics of differentiated monocytes, were significantly decreased compared with control HL60 cells. These results show that MEF2D is required in the differentiation process along the monocyte/macrophage lineage,
authors.affiliation: Department of Microbiology and Immunology, Sungkyunkwan University School of Medicine, Suwon, 440-746, South Korea.
authors.forename: H H
authors.initials: HH
authors.lastname: Shin
authors.forename: J Y
authors.initials: JY
authors.lastname: Seoh
authors.forename: H Y
authors.initials: HY
authors.lastname: Chung
authors.forename: S J
authors.initials: SJ
authors.lastname: Choi
authors.forename: M J
authors.initials: MJ
authors.lastname: Hahn
authors.forename: J S
authors.initials: JS
authors.lastname: Kang
authors.forename: M S
authors.initials: MS
authors.lastname: Choi
authors.forename: T H
authors.initials: TH
authors.lastname: Han
mesh_terms: D001483:Base Sequence; D002454:Cell Differentiation / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D002460:Cell Line; D002762:Cholecalciferol / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D018507:Gene Expression Regulation, Developmental; D018922:HL-60 Cells; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000235:genetics; D026161:MADS Domain Proteins; D064326:MEF2 Transcription Factors; D008264:Macrophages / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D018006:Myogenic Regulatory Factors; D010957:Plasmids / Q000235:genetics; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014157:Transcription Factors / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D020298:U937 Cells
chemical_list: D004268:DNA-Binding Proteins; D018950:Lipopolysaccharide Receptors; D026161:MADS Domain Proteins; D064326:MEF2 Transcription Factors; C578035:MEF2A protein, human; C578043:MEF2D protein, human; D018006:Myogenic Regulatory Factors; D014157:Transcription Factors; D002762:Cholecalciferol; D013755:Tetradecanoylphorbol Acetate